BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 29127277)

  • 41. Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth.
    Vernejoul F; Ghénassia L; Souque A; Lulka H; Drocourt D; Cordelier P; Pradayrol L; Pyronnet S; Buscail L; Tiraby G
    Mol Ther; 2006 Dec; 14(6):758-67. PubMed ID: 17000136
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance.
    MÃ¥nsson E; Flordal E; Liliemark J; Spasokoukotskaja T; Elford H; Lagercrantz S; Eriksson S; Albertioni F
    Biochem Pharmacol; 2003 Jan; 65(2):237-47. PubMed ID: 12504799
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Structure of human dCK suggests strategies to improve anticancer and antiviral therapy.
    Sabini E; Ort S; Monnerjahn C; Konrad M; Lavie A
    Nat Struct Biol; 2003 Jul; 10(7):513-9. PubMed ID: 12808445
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC).
    Kroep JR; van Moorsel CJ; Veerman G; Voorn DA; Schultz RM; Worzalla JF; Tanzer LR; Merriman RL; Pinedo HM; Peters GJ
    Adv Exp Med Biol; 1998; 431():657-60. PubMed ID: 9598147
    [No Abstract]   [Full Text] [Related]  

  • 45. Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.
    Shord SS; Patel SR
    J Exp Clin Cancer Res; 2009 Jun; 28(1):76. PubMed ID: 19500405
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthesis and biological activity of a gemcitabine phosphoramidate prodrug.
    Wu W; Sigmond J; Peters GJ; Borch RF
    J Med Chem; 2007 Jul; 50(15):3743-6. PubMed ID: 17602464
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regulation of deoxycytidine kinase expression and sensitivity to gemcitabine by micro-RNA 330 and promoter methylation in cancer cells.
    Hodzic J; Giovannetti E; Diosdado B; Adema AD; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1214-22. PubMed ID: 22132977
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Study of apoptosis induction and deoxycytidine kinase/cytidine deaminase modulation in the synergistic interaction of a novel ceramide analog and gemcitabine in pancreatic cancer cells.
    Giovannetti E; Leon LG; Bertini S; Macchia M; Minutolo F; Funel N; Alecci C; Giancola F; Danesi R; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):419-26. PubMed ID: 20544530
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
    Tang K; Zhang Z; Bai Z; Ma X; Guo W; Wang Y
    Oncol Rep; 2011 Apr; 25(4):963-70. PubMed ID: 21225236
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase.
    Sigmond J; Bergman AM; Leon LG; Loves WJ; Hoebe EK; Peters GJ
    Anticancer Drugs; 2010 Jul; 21(6):591-9. PubMed ID: 20436341
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of a UCMK/dCK fusion enzyme for gemcitabine-mediated cytotoxicity.
    Johnson AJ; Brown MN; Black ME
    Biochem Biophys Res Commun; 2011 Dec; 416(1-2):199-204. PubMed ID: 22093835
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relationship between single nucleotide polymorphisms in the deoxycytidine kinase gene and chemosensitivity of gemcitabine in six pancreatic cancer cell lines.
    Si S; Liao Q; Zhao YP; Hu Y; Zhang Q; You LL
    Chin Med J (Engl); 2011 Feb; 124(3):419-22. PubMed ID: 21362344
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.
    Kroep JR; Loves WJ; van der Wilt CL; Alvarez E; Talianidis I; Boven E; Braakhuis BJ; van Groeningen CJ; Pinedo HM; Peters GJ
    Mol Cancer Ther; 2002 Apr; 1(6):371-6. PubMed ID: 12477049
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
    Liu XQ; Wang WX; Lin L; Song ST
    Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):17-21. PubMed ID: 20211060
    [TBL] [Abstract][Full Text] [Related]  

  • 55. dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer.
    Hu Q; Qin Y; Xiang J; Liu W; Xu W; Sun Q; Ji S; Liu J; Zhang Z; Ni Q; Xu J; Yu X; Zhang B
    Cell Prolif; 2018 Aug; 51(4):e12456. PubMed ID: 29701272
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
    Giovannetti E; Mey V; Loni L; Nannizzi S; Barsanti G; Savarino G; Ricciardi S; Del Tacca M; Danesi R
    Pharmacol Res; 2007 Apr; 55(4):343-9. PubMed ID: 17296311
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Activation of deoxycytidine kinase by deoxyadenosine: implications in deoxyadenosine-mediated cytotoxicity.
    Keszler G; Virga S; Spasokoukotskaja T; Bauer PI; Sasvari-Szekely M; Staub M
    Arch Biochem Biophys; 2005 Apr; 436(1):69-77. PubMed ID: 15752710
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines.
    Pauwels B; Korst AE; Pattyn GG; Lambrechts HA; Kamphuis JA; De Pooter CM; Peters GJ; Lardon F; Vermorken JB
    BMC Cancer; 2006 May; 6():142. PubMed ID: 16734894
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular Imaging of Deoxycytidine Kinase Activity Using Deoxycytidine-Enhanced CEST MRI.
    Han Z; Li Y; Zhang J; Liu J; Chen C; van Zijl PC; Liu G
    Cancer Res; 2019 May; 79(10):2775-2783. PubMed ID: 30940660
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
    Tseng PH; Lin HP; Zhu J; Chen KF; Hade EM; Young DC; Byrd JC; Grever M; Johnson K; Druker BJ; Chen CS
    Blood; 2005 May; 105(10):4021-7. PubMed ID: 15665113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.